biostudies-literatureUnknown42(11)Hernandez-Rodriguez J<h4>Background</h4>Unprotected and fragile elderly people in nursing homes experienced the highest mortality rates during the initial coronavirus disease 2019 (COVID-19) pandemic.<h4>Objective</h4>Our aim was to study the role of two oral anti-inflammatory drugs, colchicine and prednisone, in elderly patients with COVID-19 in geriatric centers.<h4>Methods</h4>A phase II/III, randomized, controlled, multicenter clinical trial was performed in a geriatric population comparing the efficacy and safety of an oral combination of prednisone (60 mg/day for 3 days) and colchicine (at loading doses of 1-1.5 mg/day for 3 days, followed by 0.5 mg/day for 11 days) with the standard treatment, based on intravenous dexamethasone. Primary endpoints assessed the efficacy in reducing death or the modified eClinical drug investigation949-964https://www.ebi.ac.uk/biostudies/studies/S-EPMC9521010biostudies-literatureFRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.PMC9521010Lopez-Guerra NAibar JBlanco JLCarbonell IPujol ECapdevila-Reniu ABarilaro GSalazar AGomez BHospital-Vidal TAfonso FJOrtega JZamora CSacanella ESegui FDomenech GSapena VAparicio LCostafreda MIlla MCajiao KLuzko-Scheid ISMayor MIFRAGILE-COLCOVID19 Study GroupMasanes FDomenech MCasanovas GAsensio YCalvo JAraujo OGuasch NLopez-Soto AAldea-Pares AMilisenda JCSaavedra OMGomez-Caverzaschi VMacaya IVentosa HTome-Perez AFeliu MTuset MVentura RMasdeu GMontes VSanchez-Palacios VMatas-Garcia AMoreno PJGabara CEspinosa GRibot JNaval JGomez-Urbano VRios-Garces RGonzalo TRivero EPilarcikova SLadino AVinas-Esmel EGuillen MPahisa AInzitari MMorancho ACanueto MDCMontoya-Rodes MPellice MMontero MTorres-Elorza MGamez GAzuaga ABBenages NGuio AMJoyera MSanchez-Buitrago AFoncillas AMoragas NRodriguez-Nunez Ode-Daniel-Bisbe AAlemany XLledo GMHernandez-Rodriguez JGarcia-Ortega APrieto-Gonzalez SMarco DSanz AGarcia-Gutierrez CCuzco CDuran-Sanclemente JSan Miguel AGarcia-Jarque LGrafia IfalseFRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.<h4>Background</h4>Unprotected and fragile elderly people in nursing homes experienced the highest mortality rates during the initial coronavirus disease 2019 (COVID-19) pandemic.<h4>Objective</h4>Our aim was to study the role of two oral anti-inflammatory drugs, colchicine and prednisone, in elderly patients with COVID-19 in geriatric centers.<h4>Methods</h4>A phase II/III, randomized, controlled, multicenter clinical trial was performed in a geriatric population comparing the efficacy and safety of an oral combination of prednisone (60 mg/day for 3 days) and colchicine (at loading doses of 1-1.5 mg/day for 3 days, followed by 0.5 mg/day for 11 days) with the standard treatment, based on intravenous dexamethasone. Primary endpoints assessed the efficacy in reducing death or the modified e2022-01-01T00:00:00Z2022 Nov2026-05-27T19:14:03.984Z2025-02-19T03:24:14.971ZS-EPMC95210103617359610.1007/s40261-022-01201-2